We've seen basically an 86% reduction in CRP in obese subjects, and 87%-93% of subjects achieved normalized CRP below 2 milligrams per liter. This is the critical threshold that we believe will correspond to cardiovascular benefits. On the ophthalmology side, therapeutic retinal exposure of our drug enables oral treatment of diseases including diabetic macular edema, where intravitreal anti-IL-6 has shown benefit. We have a very catalyst-rich year. Our cardiovascular risk trial is starting soon and will rea ...